2020
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Kho P, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Brinton L, Buchanan DD, Chanock SJ, Chen C, Chen MM, Cheng THT, Cook LS, Crous‐Bous M, Czene K, De Vivo I, Dennis J, Dörk T, Dowdy SC, Dunning AM, Dürst M, Easton DF, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, García‐Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankinson SE, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hunter DJ, Jones A, Kraft P, Krakstad C, Lambrechts D, Le Marchand L, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Milne RL, Mints M, Nassir R, Otton G, Palles C, Pooler L, Proietto T, Rebbeck TR, Renner SP, Risch HA, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu X, Southey MC, Tham E, Tomlinson I, Trovik J, Turman C, Tyrer JP, Van Den Berg D, Wang Z, Wentzensen N, Xia L, Xiang Y, Yang HP, Yu H, Zheng W, Webb PM, Thompson DJ, Spurdle AB, Glubb DM, O'Mara TA. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal Of Cancer 2020, 148: 307-319. PMID: 32851660, PMCID: PMC7757859, DOI: 10.1002/ijc.33206.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCholesterol, HDLCholesterol, LDLEndometrial NeoplasmsFemaleGenome-Wide Association StudyHumansMendelian Randomization AnalysisRiskTriglyceridesConceptsNon-endometrioid endometrial cancerEndometrial cancer riskEndometrial cancerLDL cholesterol levelsMendelian randomization analysisBlood lipidsCholesterol levelsCancer riskRandomization analysisLower endometrial cancer riskNon-endometrioid subtypesHDL cholesterol levelsBlood lipid levelsEndometrial cancer developmentRange of cancersTwo-sample Mendelian randomization (MR) analysisPotential confounding roleHDL cholesterolColorectal cancerLipid levelsObservational studyLower riskGlobal Lipids Genetics ConsortiumCancerInconsistent associations
2019
Mendelian randomization provides support for obesity as a risk factor for meningioma
Takahashi H, Cornish AJ, Sud A, Law PJ, Disney-Hogg L, Calvocoressi L, Lu L, Hansen HM, Smirnov I, Walsh KM, Schramm J, Hoffmann P, Nöthen MM, Jöckel KH, Schildkraut JM, Simon M, Bondy M, Wrensch M, Wiemels JL, Claus EB, Turnbull C, Houlston RS. Mendelian randomization provides support for obesity as a risk factor for meningioma. Scientific Reports 2019, 9: 309. PMID: 30670737, PMCID: PMC6343031, DOI: 10.1038/s41598-018-36186-6.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueBody Mass IndexCase-Control StudiesGenetic VariationGenome-Wide Association StudyHumansMendelian Randomization AnalysisMeningiomaObesityOdds RatioRisk FactorsConceptsRisk of meningiomaMeningioma riskObesity-related traitsLipoprotein cholesterolBlood pressureRisk factorsOdds ratioLow-density lipoprotein cholesterolHigh-density lipoprotein cholesterolMendelian randomizationCause of meningiomaGenetic instrumentsDiastolic blood pressureEpidemiological observational studiesSystolic blood pressureBody mass indexBody fat percentageWaist circumferenceTotal cholesterolMass indexObservational studyMeningioma patientsMeningiomasBasal metabolic rateObesity